OncoMatch/Clinical Trials/NCT06828328
A Study of GC203 TIL in PDCA (RJ)
Is NCT06828328 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies GC203 TIL for pancreatic cancer.
Treatment: GC203 TIL — This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment regimens
Test subjects have failed standard treatment regimens
Cannot have received: allogeneic T cell therapy
History of allogeneic T cell therapy
Cannot have received: allogeneic stem cell transplantation
History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy
Cannot have received: renal replacement therapy
History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy
Lab requirements
Blood counts
Absolute count of white blood cells ≥2.5×10^9/L; Absolute count of neutrophils ≥1.5×10^9/L; Absolute count of lymphocytes ≥0.7×10^9/L; Platelet count ≥90×10^9; hemoglobin ≥90 g/L; Activated partial thromboplastin time (APTT) ≤1.5xULN (unless received anticoagulant therapy within the previous 3 days); International normalized ratio (INR) ≤1.5xULN (unless received anticoagulant therapy within the previous 3 days)
Kidney function
Serum creatinine ≤1.5mg/dL (or ≤132.6μmol/L), or clearance rate ≥50mL/min
Liver function
Serum ALT/AST ≤3×ULN (subjects with liver metastasis ≤3×ULN); Total bilirubin ≤1.5×ULN
Cardiac function
No NYHA Grade III or IV congestive heart failure, no clinically significant low blood pressure, no uncontrollable symptomatic coronary artery diseases, ejection fraction ≥35%; no severe cardiac rhythm and conduction anomaly (e.g., ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block)
Hematology and Chemistry（within 7 days prior to enrollment）: Absolute count of white blood cells≥2.5×10^9/L; Absolute count of neutropils≥1.5×10^9/L; Absolute count of lymphocytes ≥0.7×10^9/L； Platelet count≥90×10^9； hemoglobin≥90 g/L; Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min; Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN); Totol bilirubin≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06828328 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic T cell therapy, allogeneic stem cell transplantation, renal replacement therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages